Renalytix Plc (RNLXY)

Market Cap	22.47M -47.0%
Revenue (ttm)	3.00M +35.1%
Net Income	-20.40M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3,106
Open	2.800
Previous Close	3.050
Day's Range	2.800 - 2.800
52-Week Range	2.630 - 8.090
Beta	1.96
RSI	31.77
Earnings Date	Mar 18, 2026

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl...

• Industry: Prepackaged Software
• Founded: 2018
• Employees: 46
• Stock Exchange: OTCMKTS
• Ticker Symbol: RNLXY

Financial Performance

In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.